Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Main conclusions and perspectives from the collective scientific assessment of the effects of plant protection products on biodiversity and ecosystem services along the land-sea continuum in France and French overseas territories.
Pesce S, Mamy L, Sanchez W, Amichot M, Artigas J, Aviron S, Barthélémy C, Beaudouin R, Bedos C, Bérard A, Berny P, Bertrand C, Bertrand C, Betoulle S, Bureau-Point E, Charles S, Chaumot A, Chauvel B, Coeurdassier M, Corio-Costet MF, Coutellec MA, Crouzet O, Doussan I, Faburé J, Fritsch C, Gallai N, Gonzalez P, Gouy V, Hedde M, Langlais A, Le Bellec F, Leboulanger C, Margoum C, Martin-Laurent F, Mongruel R, Morin S, Mougin C, Munaron D, Nélieu S, Pelosi C, Rault M, Sabater S, Stachowski-Haberkorn S, Sucré E, Thomas M, Tournebize J, Leenhardt S. Pesce S, et al. Among authors: langlais a. Environ Sci Pollut Res Int. 2023 Apr 26. doi: 10.1007/s11356-023-26952-z. Online ahead of print. Environ Sci Pollut Res Int. 2023. PMID: 37099095 Free article.
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P. Vera P, et al. Among authors: langlais a. Lancet Oncol. 2024 Sep;25(9):1176-1187. doi: 10.1016/S1470-2045(24)00320-6. Epub 2024 Aug 9. Lancet Oncol. 2024. PMID: 39134086 Clinical Trial.
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.
Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, Leleu O, Amrane K, Berndt C, Langlais A, Morin F, Westeel V. Moro-Sibilot D, et al. Among authors: langlais a. Respir Med Res. 2024 Nov;86:101113. doi: 10.1016/j.resmer.2024.101113. Epub 2024 Apr 30. Respir Med Res. 2024. PMID: 38843598 Free article. Clinical Trial.
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Oudart JB, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M. Oudart JB, et al. Among authors: langlais a. Lung Cancer. 2024 Apr;190:107508. doi: 10.1016/j.lungcan.2024.107508. Epub 2024 Feb 19. Lung Cancer. 2024. PMID: 38428265 Free article. Clinical Trial.
52 results